Adjuvant Pembrolizumab Versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Overview

Journal Cancer Discov

Specialty Oncology

Date 2021 Nov 12

PMID 34764195

Citations 34

Authors

Kenneth F Grossmann

Megan Othus

Sapna P Patel

Ahmad A Tarhini

Vernon K Sondak

Michael V Knopp

Teresa M Petrella

Thach-Giao Truong

Nikhil I Khushalani

Justine V Cohen

Elizabeth I Buchbinder

Kari Kendra

Pauline Funchain

Karl D Lewis

Robert M Conry

Bartosz Chmielowski

Ragini R Kudchadkar

Douglas B Johnson

Hongli Li

James Moon

Zeynep Eroglu

Brian Gastman

Magdalena Kovacsovics-Bankowski

Krishna S Gunturu

Scot W Ebbinghaus

Sama Ahsan

Nageatte Ibrahim

Elad Sharon

Larissa A Korde

John M Kirkwood

Antoni Ribas

Affiliations

Soon will be listed here.

Abstract

Significance: Adjuvant PD-1 blockade therapy decreases the rates of recurrence, but not survival, in patients with surgically resectable melanoma, substituting the prior standard-of-care immunotherapies for this cancer. See related commentary by Smithy and Shoushtari, p. 599. This article is highlighted in the In This Issue feature, p. 587.

Citing Articles

The Landmark Series: Melanoma and Adjuvant Therapy.

Lowe M, Delman K, Ollila D Ann Surg Oncol. 2025; .

PMID: 40067605 DOI: 10.1245/s10434-025-17102-5.

Adjuvant immunotherapy in the modern management of resectable melanoma: current status and outlook to 2028.

Donia M, Jespersen H, Jalving M, Lee R, Eriksson H, Hoeller C ESMO Open. 2025; 10(3):104295.

PMID: 39954389 PMC: 11872484. DOI: 10.1016/j.esmoop.2025.104295.

Adjuvant Proton Beam Radiation Therapy for Sinonasal Mucosal Melanoma.

Takayesu J, Parvathaneni U, Laramore G, Panjwani N, Sillings J, Futran N Cancer Rep (Hoboken). 2025; 8(2):e70111.

PMID: 39907094 PMC: 11795273. DOI: 10.1002/cnr2.70111.

Is pathological response an adequate surrogate marker for survival in neoadjuvant therapy with immune checkpoint inhibitors?.

Sugiyama K, Gordon A, Popat S, Okines A, Larkin J, Chau I ESMO Open. 2025; 10(2):104122.

PMID: 39874902 PMC: 11808614. DOI: 10.1016/j.esmoop.2024.104122.

Adjuvant Systemic Immunotherapies for Resected Stage III Melanoma: A Single-Centre Retrospective Clinical Practice Review.

Lefas A, Cinar C, Sreekumar S, Pakzad F, Koliou P Int J Mol Sci. 2025; 26(2).

PMID: 39859464 PMC: 11765691. DOI: 10.3390/ijms26020750.

References

Eggermont A, Blank C, Mandala M, Long G, Atkinson V, Dalle S . Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021; 22(5):643-654. DOI: 10.1016/S1470-2045(21)00065-6. View

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

Kirkwood J, Strawderman M, Ernstoff M, Smith T, Borden E, Blum R . Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996; 14(1):7-17. DOI: 10.1200/JCO.1996.14.1.7. View

Eggermont A, Blank C, Mandala M, Long G, Atkinson V, Dalle S . Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018; 378(19):1789-1801. DOI: 10.1056/NEJMoa1802357. View

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Rutkowski P, Lao C . Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019; 381(16):1535-1546. DOI: 10.1056/NEJMoa1910836. View

Spiessens B, Debois M . Adjusted significance levels for subgroup analyses in clinical trials. Contemp Clin Trials. 2010; 31(6):647-56. DOI: 10.1016/j.cct.2010.08.011. View

Huang A, Orlowski R, Xu X, Mick R, George S, Yan P . A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019; 25(3):454-461. PMC: 6699626. DOI: 10.1038/s41591-019-0357-y. View

Balch C, Gershenwald J, Soong S, Thompson J, Atkins M, Byrd D . Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27(36):6199-206. PMC: 2793035. DOI: 10.1200/JCO.2009.23.4799. View

Eggermont A, Chiarion-Sileni V, Grob J, Dummer R, Wolchok J, Schmidt H . Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015; 16(5):522-30. DOI: 10.1016/S1470-2045(15)70122-1. View

10.

Daud A, Wolchok J, Robert C, Hwu W, Weber J, Ribas A . Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. J Clin Oncol. 2016; 34(34):4102-4109. PMC: 5562434. DOI: 10.1200/JCO.2016.67.2477. View

11.

Weber J, Mandala M, Del Vecchio M, Gogas H, Arance A, Cowey C . Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017; 377(19):1824-1835. DOI: 10.1056/NEJMoa1709030. View

12.

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D . Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2014; 372(1):30-9. DOI: 10.1056/NEJMoa1412690. View

13.

Ascierto P, Del Vecchio M, Mandala M, Gogas H, Arance A, Dalle S . Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020; 21(11):1465-1477. DOI: 10.1016/S1470-2045(20)30494-0. View

14.

Rozeman E, Menzies A, van Akkooi A, Adhikari C, Bierman C, van de Wiel B . Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019; 20(7):948-960. DOI: 10.1016/S1470-2045(19)30151-2. View

15.

Amaria R, Reddy S, Tawbi H, Davies M, Ross M, Glitza I . Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018; 24(11):1649-1654. PMC: 6481682. DOI: 10.1038/s41591-018-0197-1. View

16.

Dummer R, Ascierto P, Gogas H, Arance A, Mandala M, Liszkay G . Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018; 19(5):603-615. DOI: 10.1016/S1470-2045(18)30142-6. View

17.

Weber J, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M . Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). J Clin Oncol. 2022; 41(3):517-527. PMC: 9870220. DOI: 10.1200/JCO.22.00533. View

18.

Dummer R, Hauschild A, Santinami M, Atkinson V, Mandala M, Kirkwood J . Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020; 383(12):1139-1148. DOI: 10.1056/NEJMoa2005493. View

19.

Robert C, Schachter J, Long G, Arance A, Grob J, Mortier L . Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015; 372(26):2521-32. DOI: 10.1056/NEJMoa1503093. View

20.

Long G, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J . Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014; 371(20):1877-88. DOI: 10.1056/NEJMoa1406037. View